Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan W Warner

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
BJU International|October 4, 2018
DNA repair defects in prostate cancer: impact for screening, prognostication and treatmentEvan W Warner, Steven M Yip, Kim N Chi, et al.
Clinical Genitourinary Cancer|January 23, 2016
Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate CancerEdmund C P Chedgy, Matti Annala, Kevin Beja, et al.
European Urology|March 6, 2017
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate CancerMatti Annala, Werner J Struss, Evan W Warner, et al.
JAMA Oncology|May 6, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W Wyatt, Arun A Azad, Stanislav V Volik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2017
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation TherapyHimisha Beltran, Alexander W Wyatt, Edmund C Chedgy, et al.
Journal of the National Cancer Institute|September 7, 2023
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trialTakayuki Sumiyoshi, Xiaofei Wang, Evan W Warner, et al.
Cancer Discovery|January 26, 2018
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Gillian Vandekerkhove, Daniel Khalaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2019
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Simon Y F Fu, Cameron Herberts, et al.
NPJ Precision Oncology|March 14, 2023
A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomesElie J Ritch, Cameron Herberts, Evan W Warner, et al.
European Urology|January 15, 2019
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate CancerGillian Vandekerkhove, Werner J Struss, Matti Annala, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
BJU International|October 4, 2018
DNA repair defects in prostate cancer: impact for screening, prognostication and treatmentEvan W Warner, Steven M Yip, Kim N Chi, et al.
Clinical Genitourinary Cancer|January 23, 2016
Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate CancerEdmund C P Chedgy, Matti Annala, Kevin Beja, et al.
European Urology|March 6, 2017
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate CancerMatti Annala, Werner J Struss, Evan W Warner, et al.
JAMA Oncology|May 6, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W Wyatt, Arun A Azad, Stanislav V Volik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2017
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation TherapyHimisha Beltran, Alexander W Wyatt, Edmund C Chedgy, et al.
Journal of the National Cancer Institute|September 7, 2023
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trialTakayuki Sumiyoshi, Xiaofei Wang, Evan W Warner, et al.
Cancer Discovery|January 26, 2018
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Gillian Vandekerkhove, Daniel Khalaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2019
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Simon Y F Fu, Cameron Herberts, et al.
NPJ Precision Oncology|March 14, 2023
A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomesElie J Ritch, Cameron Herberts, Evan W Warner, et al.
European Urology|January 15, 2019
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate CancerGillian Vandekerkhove, Werner J Struss, Matti Annala, et al.
Pageof 2